Administration of IGF-1 following ischemic and/or hemorrhagic stroke attenuates microglial activation, inflammation, and ROS (Serhan et al., 2020; Sun Z. et al., 2020). This evidence concerns the gene IGF1 and hemorrhagic stroke.